Oxidative stress aggravates
brain injury following
ischemia/reperfusion (I/R). We previously showed that ubiquilin-1 (Ubqln1), a
ubiquitin-like protein, improves proteostasis and protects brains against oxidative stress and I/R-induced
brain injury. Here, we demonstrate that a small molecule compound, L-2-oxothiazolidine-4-carboxylic
acid (OTC) that functions as a precursor of
cysteine, upregulated Ubqln1 and protected cells against
oxygen-
glucose deprivation-induced cell death in neuronal cultures. Further, the administration of OTC either at 1 h prior to
ischemia or 3 h after the reperfusion significantly reduced
brain infarct injury and improved behavioral outcomes in a
stroke model. Administration of OTC also increased
glutathione (GSH) level and decreased
superoxide production, oxidized
protein, and
neuroinflammation levels in the penumbral cortex after I/R in the
stroke mice. Furthermore, I/R reduced both Ubqln1 and the
glutathione S-transferase protein levels, whereas OTC treatment restored both
protein levels, which was associated with reduced
ubiquitin-conjugated
protein level. Interestingly, in the Ubqln1 knockout (KO) mice, OTC treatment showed reduced neuroprotection and increased
ubiquitin-conjugated
protein level when compared to the similarly treated non-KO mice following I/R, suggesting that OTC-medicated neuroprotection is, at least partially, Ubqln1-dependent. Thus, OTC is a potential therapeutic agent for
stroke and possibly for other
neurological disorders and its neuroprotection involves enhanced proteostasis.